ClinicalTrials.gg
RecruitingNCT07333274Updated Jan 12, 2026

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of Nimotuzumab and intensity-modulated technique(IMRT) in Head & Neck Squamous Cell Carcinoma and Head & Neck Cancer, sponsored by Shandong Cancer Hospital and Institute. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Shandong Cancer Hospital and Institute · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck — 6 open to participants now, 6 under way, 2 of them phase 3. nimotuzumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
3rd of 12
335 · median 93
Started
2026
with 3 others
Phase 3
2 of 12
1 open now
Registered
10th of 12
by date
Lead sponsor
1 of 12
Shandong Cancer Hospital and Institute

Among the 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 2 in phase 3, and was the 10th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About nimotuzumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This is an open-label, prospective, randomized, Phase III, international multicenter clinical study to compare radiotherapy plus nimotuzumab versus radiotherapy alone in platinum-ineligible patients with locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC),

Read the detailed description

This is an open-label, prospective, randomized, Phase III, international multicenter clinical study to compare radiotherapy plus nimotuzumab versus radiotherapy alone in platinum-ineligible patients with locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC), The study aims to evaluate the efficacy and safety of radiotherapy combined with nimotuzumab in platinum-ineligible patients with (LA-HNSCC).Around 70 study sites were involved in the trial.

03

Conditions studied

  • Head & Neck Squamous Cell Carcinoma
  • Head & Neck Cancer

Keywords

  • Nimotuzumab
  • Radiotherapy
  • locoregionally advanced head and neck squamous cell carcinoma
  • LA-HNSCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible subjects must meet all of the following:

    • Age ≥18 years.
    • confirmed stage III-IVB (AJCC 8th edition) head and neck squamous cell carcinoma (including cancers of the oral cavity, oropharynx, hypopharynx, and larynx).
    • Unsuitable for surgical treatment (defined as: due to patient condition or tumor factors [T3-4 N0-3 M0, or T1-2 N2-3 M0] or medical reasons, surgery is not feasible; or an R0 resection is not achievable).
    • Suitable for definitive radiotherapy with curative intent.
    • At least one of the following reasons for being unsuitable for cisplatin-based chemotherapy:
  • Age ≥65 years and, in the investigator's judgment, unable to tolerate chemotherapy;
  • Performance Status >2 (if this criterion is met, the ECOG criterion listed below may be waived);
  • Renal dysfunction: (CrCl) \<50 mL/min (Cockcroft-Gault) (if this criterion is met, the renal function criterion listed below may be waived);
  • Severe tinnitus or hearing loss (requires a hearing aid or audiometry shows ≥25 dB loss at two consecutive frequencies);
  • Peripheral neuropathy > Grade 1;
  • Inability to receive intravenous hydration (e.g., due to cardiac dysfunction) or other comorbidities, per investigator's judgment.

    • Provide tumor tissue, whenever possible, for EGFR testing; for oropharyngeal cancer, provide tissue for HPV/p16 testing if feasible (no need to retest if previously tested).
    • ECOG Performance Status 0-1 (or Performance Status ≥80).
    • At least one per 1.1.
    • Expected survival ≥6 months.
    • Adequate hematologic function: WBC ≥4×10\^9/L; ≥1.5×10\^9/L; ≥100×10\^9/L; ≥90 g/L.
    • Adequate renal function: serum creatinine ≤1.5× or CrCl ≥60 mL/min (Cockcroft-Gault):
  • Female CrCl = (140 - age) × weight (kg) × 0.85 / (72 × S_cr [mg/dL])
  • Male CrCl = (140 - age) × weight (kg) × 1.00 / (72 × S_cr [mg/dL])

    • Adequate liver function: total ≤1.5×ULN; ≤2.5×ULN; ALT ≤2.5×ULN.
    • Voluntary participation: signed written and ability to comply with visits and procedures.

Exclusion criteria

Exclusion Criteria:

  • Any of the following excludes enrollment:

    • Receipt of a inhibitor, EGFR monoclonal antibody, EGFR-TKI, or anti-angiogenic agent within 4 weeks prior to enrollment.
    • Participation in another interventional clinical trial within 30 days prior to screening.
    • History of other (except cured basal cell carcinoma of the skin).
    • History of primary immunodeficiency.
    • Uncontrolled comorbid conditions (e.g., congestive heart failure, severe pulmonary disease, severe liver disease, psychiatric illness).
    • Known infection, or active viral hepatitis or active tuberculosis.
    • Major surgery within 90 days before first study treatment, or planned surgery during the study.
    • Known allergy to nimotuzumab or its .
    • Deemed unsuitable to participate by the investigator.
    • Unwilling or unable to sign .
    • Receipt of a within 30 days before first dose.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
335 participants (estimated)

Study arms

  • Experimental
    Radiotherapy plus nimotuzumab

    radiotherapy plus nimotuzumab

    Drug: Nimotuzumab · Radiation: intensity-modulated technique(IMRT)

  • Active comparator
    Radiotherapy alone in LA-HNSCC

    Radiation: intensity-modulated technique(IMRT)

Interventions

  • Treatment regimen: Nimotuzumab(Experimental Group): nimotuzumab injection 200 mg IV once weekly (QW) for 7 weeks (concurrent with radiotherapy).

    Also known as: Nimotuzumab injection

  • Radiationintensity-modulated technique(IMRT)

    Treatment regimen: Radiotherapy (both groups): intensity-modulated technique (photon IMRT or proton IMPT); total dose 70 Gy (2.0 Gy per fraction, 35 fractions), 5 fractions per week.

    Also known as: photon IMRT, proton IMPT, intensity-modulated technique

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    the proportion of patients in a clinical study who remain free of disease progression (including local recurrence, regional lymph node metastasis, distant metastasis, or second primary malignancy) and have not died from any cause within 2 years from the start of treatment (or randomization in randomized controlled trials).

    Time frame: 24 months after treatment initiation

Secondary outcomes

  1. 2-year locoregional control (LRC) rate.

    the proportion of patients in a clinical study who remain free of disease progression within 2 years from the start of treatment (or randomization in randomized controlled trials).

    Time frame: 24 months after treatment initiation

  2. 2-year distant metastasis rate.

    the prproportion of participants with distant metastatic progression within 24 months,

    Time frame: 24 months after treatment initiation

  3. Overall Survival (OS)

    the prproportion of participants surviving at 2 years after enrolling,regardless of disease status.

    Time frame: 24 months after treatment initiation

  4. Objective Response Rate (ORR; CR+PR by RECIST 1.1).

    the proportion of patients with measurable malignant tumors who achieve a complete response (CR) or partial response (PR)

    Time frame: 24 months after treatment initiation

  5. Quality of Life (QoL)

    Time frame: 24 months after treatment initiation

07

Study locations

1 of 1 sites recruiting
  • Shandong First Medical University Affiliated Cancer Hospital
    Shandong, Province, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2028, 24 months later.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 24 months is below that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2025
First posted
Jan 12, 2026
StartEst.
Jan 5, 2026
Primary completionEst.
Jan 5, 2028
CompletionEst.
Jan 5, 2030
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07333274
Responsible party
Man Hu (Shandong First Medical University Affiliated Cancer Hospital, Shandong Cancer Hospital and Institute) — Principal investigator
First posted
Jan 12, 2026
Start date
Jan 5, 2026 (estimated)
Primary completion
Jan 5, 2028 (estimated)
Completion
Jan 5, 2030 (estimated)
Last update
Jan 12, 2026

Study contacts

Man Hu
Contact
hu5770@sina.com
86+15806698606 ext. (0531)67626151
Man Hu
principal investigator · Shandong First Medical University Affiliated Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nimotuzumab

Start the discussion